Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study

Next Previous
Trial Profile

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ASPIRE

Most Recent Events

  • 31 Oct 2018 Results assessing levels of residual viremia by an ultrasensitive viral load assay to determine whether dolutegravir and lamivudine presented at the 14th International Congress on Drug Therapy and HIV Infection.
  • 27 Jul 2018 Results assessing genital HIV-1 shedding with Dolutegravir plus Lamivudine dual therapy in patients from ASPIRE and ACTG-A5353 studies (n=41) presented at the 22nd International AIDS Conference
  • 26 Dec 2017 Primary endpoint has been met. (Virologic failure rate) as per results published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top